Publications by authors named "G Hirokane"
Article Synopsis
- * Researchers analyzed PAX plasma levels and identified serotonin transporter gene variations, while measuring PD severity using a specific scale.
- * Findings showed that higher plasma levels of PAX, specific gene variants, and the presence of other physical illnesses reduced the initial positive effects of PAX in treating PD.
Article Synopsis
- The study examines how plasma levels of the antidepressant paroxetine affect the clinical response in patients with panic disorder.
- Twenty-one Japanese patients diagnosed with panic disorder were treated with a low dose of paroxetine (10 mg/day) for 2 weeks, and symptom improvement was measured using the Panic and Agoraphobia Scale (PAS).
- Results indicated that patients with plasma levels of paroxetine below 20 ng/mL showed significantly better improvement compared to those with levels above this threshold, suggesting a potential upper limit for effective dosages in early treatment.
The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients.
Prog Neuropsychopharmacol Biol Psychiatry
May 2006
The authors investigated the impact of the CYP2D6 genotypes on the plasma concentration of paroxetine (PAX) in 55 Japanese psychiatric patients. They were administered 10 to 40 mg/day (24+/-10.0 mg/day) of PAX and maintained at the same daily dose for at least two weeks to obtain the steady-state concentrations.
View Article and Find Full Text PDFWe investigated the effect of CYP2D6 genotypes on plasma levels of haloperidol (HAL) and reduced haloperidol (RHAL) in 88 Japanese schizophrenic inpatients being treated with HAL. Some subjects carrying CYP2D6*5 allele (CYP2D6*1/CYP2D6*5, CYP2D6*5/CYP2D6*10) showed extremely high concentrations of both HAL and RHAL, and the groups with CYP2D6*5 allele seemed to have higher plasma concentrations of HAL (1.14+/-0.
View Article and Find Full Text PDF